在BRCA1和BRCA2相关的乳腺癌中新辅助性PARP抑制剂编程:PARTNER,一个随机的II/III期试验
Jean E Abraham1,2, Lenka Oplustil O'Connor3, Louise Grybowicz4
1Precision Breast Cancer Institute, Department of Oncology, University of Cambridge, Cambridge, United Kingdom. ja344@cam.ac.uk.
Nature communications
|May 13, 2025
概括
一个新的化疗方案,将olaparib与卡博普拉丁和帕克利塔克塞尔结合起来,显示了早期生殖线BRCAm乳腺癌患者的改善生存结果. 这种组合疗法显示出显著的整体生存益处,需要在更大的临床试验中进一步调查.
科学领域:
- 在瘤学瘤学.
- 遗传学 是一个遗传学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 多 (ADP-ribose) 聚合酶抑制剂 (PARPi) 在生殖 BRCA1/2 致病变体 (gBRCAm) 癌症中有效.
- 血液学毒性往往限制了化疗和PARPi的结合治疗.
- 临床前模型表明,使用Olaparib和carboplatin的特定时间表可以保持抗瘤活性,同时避免增强的毒性.
研究的目的:
- 在gBRCAm乳腺癌患者中研究一种新的新辅助治疗方案,将olaparib与化疗结合起来.
- 与单独的化疗相比,评估这种联合治疗方案的安全性,耐受性和有效性.
主要方法:
- 一个随机的II-III期受控试验 (PARTNER,NCT03150576) 用于gBRCAm乳腺癌患者.
- 研究部门:卡博普拉丁,帕克利塔克塞尔和奥拉巴里布4个周期,然后进行环素化疗.
- 控制臂:仅使用化疗.
主要成果:
- 研究组 (64.1%) 和对照组 (69.8%) 之间病理完整反应率没有显著差异.
- 在研究小组中,显著改善了36个月无事件生存率 (96.4%vs. 80.1%,p=0.04) 和整体生存率 (100%vs. 88.2%,p=0.04).
- 在无复发存活率,远程无疾病存活率,局部无复发存活率或第二次癌症的时间方面没有显著差异.
结论:
- 该PARTNER试验确定了一个安全和耐受的计划,将新辅助化疗与olaparib结合起来,用于早期的gBRCAm乳腺癌.
- 这种特定的组合疗法表明了依赖于时间表的整体生存益处.
- 建议在更大的试验中进一步确认.
相关概念视频
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Inhibition of Cdk Activity
4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K


